AstraZeneca’s Dapagliflozin gets extended indication approval from DCGI to treat heart failure in adults Read more
Empagliflozin reduces hospitalisation risk for heart-failure and cardiovascular death by 21 per cent, shows Boehringer Ingelheim’s Emperor-Preserved trial Read more
Empagliflozin reduced risk of death and hospitalisation for heart failure by 25 per cent in adults Read more
Novartis digital initiatives to create awareness of heart failure can positively impact patients’ lives in India: GlobalData Read more